Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 29;13(2):e70102.
doi: 10.1002/ccr3.70102. eCollection 2025 Feb.

Bloodless Management of Severe Refractory ITP and Acute Hemorrhage in a Jehovah's Witness Patient

Gagandeep Kaur  1 , Shanley Banaag  2 , Lee Hong  2 , Charisma Mylavarapu  2 , Yuri Kim  1 , John Garrett  3 , Emily Nagler  2
Affiliations

Bloodless Management of Severe Refractory ITP and Acute Hemorrhage in a Jehovah's Witness Patient

Gagandeep Kaur et al. Clin Case Rep. .

Abstract

In patients with severe refractory immune thrombocytopenia (ITP), especially those unable to receive blood transfusions due to religious beliefs, alternative non-cytotoxic therapies are important to avoid worsening cytopenias. Immunomodulatory agents such as mycophenolate mofetil and daratumumab should be used alongside traditional therapies including steroids, IVIG and rituximab.

Keywords: Jehovah's Witness; bloodless management; erythropoietin; hemorrhage; immune thrombocytopenia.

PubMed Disclaimer

Conflict of interest statement

E.N. served on advisory boards for Protagonist, Sobi, and Pharmaessentia.

Figures

FIGURE 1
FIGURE 1
Platelet count over time during hospitalization. Medications administered over time are labeled with arrows and significant events are labeled with dashed arrows.
See this image and copyright information in PMC

References

    1. Stasi R., “How to Approach Thrombocytopenia,” Hematology. American Society of Hematology. Education Program 2012 (2012): 191–197, 10.1182/asheducation-2012.1.191. - DOI - PubMed
    1. Schoonen W. M., Kucera G., Coalson J., et al., “Epidemiology of Immune Thrombocytopenic Purpura in the General Practice Research Database,” British Journal of Haematology 145, no. 2 (2009): 235–244. - PubMed
    1. Christiansen C. F., Bahmanyar S., Ghanima W., et al., “Chronic Immune Thrombocytopenia in Denmark, Sweden and Norway: The Nordic Country Patient Registry for Romiplostim,” EClinicalMedicine 14 (2019): 80–88. - PMC - PubMed
    1. He R., Reid D. M., Jones C. E., and Shulman N. R., “Spectrum of Ig Classes, Specificities, and Titers of Serum Antiglycoproteins in Chronic Idiopathic Thrombocytopenic Purpura,” Blood 83 (1994): 1024–1032. - PubMed
    1. Boylan B., Chen H., Rathore V., et al., “Anti‐GPVI‐Associated ITP: An Acquired Platelet Disorder Caused by Autoantibody‐Mediated Clearance of the GPVI/FcRgamma‐Chain Complex From the Human Platelet Surface,” Blood 104 (2004): 1350–1355, 10.1182/blood-2004-03-0896. - DOI - PubMed

LinkOut - more resources